Avocate de formation, Anie Perrault est directrice générale de BIOQuébec, l’association québécoise des entreprises en biotechnologie et des organisations de recherche contractuelles en sciences de la vie depuis 2013. Mme Perrault est également médiatrice accréditée et membre à temps partiel (juge administratif) du Tribunal canadien des droits de la personne. En février 2013, Mme Perrault a reçu le titre d’administratrice de sociétés certifiée (ASC) du Collège des administrateurs de sociétés de l’Université Laval. Elle est présidente du conseil d’administration de Génome Québec (2019) et administratrice depuis 2016, membre du conseil d’administration de Loto-Québec (2011) et de l’Université de Sherbrooke (2016-2019) et membre du c.a. de la Fondation Jeanne-Mance.

Brian Bloom is co-founder, Chairman and CEO of Bloom Burton & Co. By forging unique relationships with international healthcare-specialized investors, Brian raises capital for Canadian healthcare companies while helping investors realize returns. Brian serves on the Board of Directors of Triumvira Immunologics, Appili Therapeutics, Satellos Bioscience and Qing Bile Therapeutics. Brian is also on the Faculty of Science Dean’s Advisory Board at McMaster University.

Vincent Nadeau joined Bloom Burton & Co. in February 2015. He brings scientific, R&D, business, IP and regulatory insights and advice to healthcare companies, supporting their growth and the monetization of exciting life science technologies and products in Canada. Vincent’s expertise also supports newly formed Bloom Burton incubated companies, working with management teams to build value early on in their corporate life. Vincent holds a PhD in Biochemistry from the University of Toronto with a focus on membrane protein folding and cystic fibrosis research. He also obtained a Bachelor of Science in Biochemistry from McGill University.

David Martin serves as the Managing Director and Head of Equity Research of Bloom Burton & Co. By seeking out and researching publicly traded healthcare and emerging biotechnology companies, he identifies opportunities that are differentiated and undervalued, thereby providing for Bloom Burton’s clients investment ideas with the potential for substantial returns. David also serves on the Board of Directors of The NanoMedicines Innovation Network (NMIN). Before joining Bloom Burton, David most recently served as Vice President, Corporate Development and Investor Relations at a high growth medical device company. Earlier in his career, he led the Healthcare Equity Research team at one of Canada’s largest independent investment dealers, and he has also worked in the clinical diagnostics industry. David received a Ph.D. Biochemistry from the University of Western Ontario for oncology research which he conducted at the London Regional Cancer Centre and at the Princess Margaret Hospital. He also holds a MBA degree from the Richard Ivey School of Business.